公司资料
Veracyte 股价、新闻与催化剂
- 股票代码:
- VCYT
- 交易所:
- NASDAQ
- 行业:
- MedTech
- 所在地:
- United States
股票表现
45.81 USD (+3.67%)
收盘价
最后更新: 2026年10月2日
3.81B USD
市值
股价为何变动
截至 2026年10月2日，VCYT 上涨 3.67%，收于 $45.81。当前新闻监测窗口内未发现新的同公司新闻。
公司概览
Cancer Diagnostics Company
Veracyte develops molecular tests that analyze tumor biology to support diagnosis, prognosis, treatment selection, and disease monitoring across multiple cancer types.
Decipher Urologic Diagnostics
The Decipher franchise includes genomic classifiers for prostate and bladder cancer. These tests help clinicians assess disease aggressiveness and inform treatment intensity at key decision points.
Afirma Thyroid Testing
Afirma evaluates indeterminate thyroid nodules to help determine which patients may avoid diagnostic surgery and which may require further intervention. The platform also generates molecular information that can support treatment planning.
Breast and MRD Expansion
Prosigna estimates recurrence risk in early-stage hormone-receptor-positive breast cancer, while TrueMRD uses whole-genome sequencing to monitor molecular residual disease, initially in muscle-invasive bladder cancer.
Integrated Diagnostics Platform
Veracyte combines genomic and clinical data, bioinformatics, AI, laboratory operations, and evidence generation. The portfolio also includes programs in lung cancer and interstitial lung disease, creating opportunities across the diagnostic and treatment continuum.
未来催化剂
近期新闻
新闻标题由机器翻译，详情为英文原文。
相似股票
商业成熟度、治疗领域或催化剂模式相近的同行公司。